Stegmayr 2005.

Methods	Study design: open RCT Time frame: from February 1998 Follow‐up period: 5 years
Participants	Country: Sweden Setting: multicentre Inclusion criteria: GFR < 30 mL/min/1.73 m² Number (treatment/control): 70/73 Age (mean ± SD) years: treatment group (67.8 ± 12.4); control group (69.4 ± 10.2) Sex (M/F): treatment group (48/22); control group (51/22) Exclusion criteria: aged < 18 years; fertile women not taking oral contraceptives; pregnant or lactating women; active liver disease; history of adverse reactions to statins; patients with functioning kidney transplant not on dialysis; patients on waiting list for transplantation; those on protein‐restricted diet < 40 g protein/day; poor compliance to medication and follow‐up; history of progressive malignancy and life expectancy < 6 months
Interventions	Treatment group Atorvastatin Dose: 10 mg/d Treatment duration: 35 ± 20.1 months (range 1 to 67 months) Control group Placebo Treatment duration: 31 ± 21.4 months (range 0.5 to 69 months)
Outcomes	All‐cause mortality AMI need for PTCA CABG Lipid profile
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	NR
Allocation concealment (selection bias)	Low risk	Randomisation by means of a telephone call to the study data centre where sealed envelopes were drawn
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded
Blinding of outcome assessment (detection bias) All outcomes	High risk	Not blinded
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients analysed
Selective reporting (reporting bias)	Low risk	Published reports included all expected outcomes
ITT analysis	Low risk	Conducted